MILAN, July 16 (Class Editori) -- Medica, an integrated group in the biomedical and MedTech sectors listed on Egm, has increased its stake in the newly established Chinese Medico MedTech to 32%, for a total consideration of 11.2 million yuan (approximately 1.4 million euros).
Analysts at Intesa Sanpaolo note that the Chinese market contributes between 10% and 15% to the group's revenues, and they believe the transaction aligns with the company's strategy of strengthening its presence in international markets. Medica's acquisition of an initial 20% stake last January was aimed at directly entering the Chinese market, leveraging “the company's technological capabilities with Huisheng's product registration capabilities and Hotin's commercial strengths”.
The Suzhou-based MedTech is indeed controlled by Suzhou Huisheng Medical Science & Technology Co. Ltd., with Shanghai Hotin Trading Co. Ltd. as the other minority partner, for a total consideration of 7 million RMB. Through this investment, Medica has gained a direct presence in the Chinese market, allowing it to strengthen its market share in a complex territory, particularly within the chronic division, and better address the commercial challenges that arise in a rapidly developing region by leveraging Medica's advanced technological expertise alongside Huisheng's strong product registration capabilities and Hotin's commercial strengths.
Medica Group has been active since 1985 in the biomedical district of Mirandola, where it was founded by Luciano Fecondini, the current chairman, and Andrea Bocchi. Innovation and the development of new products for blood purification have always been the company's core business. Through the work of two highly dynamic R&D groups (electromedical, membranes, and disposables), the group has ventured into medical fields such as dialysis, CRRT, ECCO2, apheresis, DFPP, CHF, HIPEC, organ perfusion for transplant, regenerative medicine, gastroenterology, urodynamics, and oxygen humidification. It also operates in microbiological water purification and industrial automation for the biomedical sector.
Over the years, R&D activities have been integrated with highly automated production capabilities across various facilities and through several commercial entities, both in Italy and abroad.
The critical success factors for the group include:
· Extrusion of hollow fiber membranes for hemofiltration, plasma exchange, cascade filtration, oxygen humidification, ultrafiltration, and water microfiltration.
· The vertical integration of the group, highlighted by its ability to manage not only the design and development of disposable medical devices and electromedical machines but also the refinement of automation technologies necessary for their production.
· Strong inclination towards exports, with sales in over 60 countries.
In 2023, Medica Group closed its consolidated financial statements with revenues of 80 million euros (compared to 50.9 million euros in 2022), EBITDA of 11.7 million euros (11.2 million euros in 2022), EBIT of 4.6 million euros (5.3 million euros in 2022), and a net profit of 2.5 million euros (4 million euros in 2022).
(Source:Class Editori)
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
